From: Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
Total | cJADAS-71 < =1.5 or < =2.5a | cJADAS-71 > 1.5 or > 2.5b | |
---|---|---|---|
Patients, n (%) | 68 | 35 | 33 |
Female, n (%) | 47 (69) | 24 (69) | 23 (70) |
JIA Subcategory, n (%) | |||
Oligoarticular JIA persistent | 27 (40) | 12 (34) | 15 (45) |
Oligoarticular JIA extended | 6 (9) | 3 (9) | 3 (9) |
Polyarticular JIA RF- | 15 (22) | 9 (26) | 6 (18) |
Polyarticular JIA RF+ | 5 (7) | 1 (3) | 4 (12) |
Psoriatic Arthritis | 7 (10) | 6 (17) | 1 (3) |
Enthesitis Related Arthritis | 5 (7) | 2 (6) | 3 (9) |
Systemic JIA | 1 (2) | 1 (3) | 0 (−) |
Undifferentiated JIA | 2 (3) | 1 (3) | 1 (3) |
Age at visit, median (IQR), y | 13.6 (10.5–16.4) | 13.3 (11.0–15.6) | 14.1 (9.0–16.9) |
Age at disease onset, median (IQR), y | 7.6 (3.1–12.1) | 6.7 (3.0–11.2) | 9.4 (3.4–13.6) |
Disease duration, median (IQR), y | 4.6 (1.5–7.7) | 6.4 (2.7–8.4) | 2.4 (1.2–6.3) |
cJADAS-71, median (IQR) | 1.8 (0.1–6.1) | 0.1 (0.0–0.7) | 6.5 (4.0–9.5) |
Treatment at Visit | |||
Biologic DMARD, n (%) | |||
Adalimumab | 17 (25) | 10 (29) | 7 (21) |
Etanercept | 8 (12) | 4 (11) | 4 (12) |
Golimumab | 4 (6) | 0 (−) | 4 (12) |
Synthetic DMARD, n (%) | |||
Methotrexate | 30 (44) | 17 (49) | 13 (39) |
Other DMARD | 5 (7) | 3 (9) | 2 (6) |
No Biologic or Synthetic DMARD n (%) | 24 (35) | 12 (34) | 12 (36) |